BioScrip (BIOS) Hits New 1-Year Low at $1.68
BioScrip Inc (NASDAQ:BIOS) reached a new 52-week low on Thursday . The company traded as low as $1.68 and last traded at $1.73, with a volume of 33625 shares traded. The stock had previously closed at $1.72.
A number of research analysts recently commented on the company. BidaskClub downgraded BioScrip from a “sell” rating to a “strong sell” rating in a research note on Wednesday, March 6th. Canaccord Genuity dropped their price target on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a research note on Monday, March 18th. Stephens downgraded BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target for the company. in a research note on Monday, March 18th. Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Finally, TheStreet downgraded BioScrip from a “c-” rating to a “d” rating in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $4.70.
The company has a market cap of $219.15 million, a P/E ratio of -3.49 and a beta of 0.69.
A number of institutional investors have recently added to or reduced their stakes in BIOS. Maven Securities LTD bought a new position in BioScrip in the fourth quarter valued at about $45,000. FNY Investment Advisers LLC grew its position in BioScrip by 840.9% in the first quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock valued at $50,000 after acquiring an additional 22,343 shares during the last quarter. Caxton Associates LP bought a new position in BioScrip in the fourth quarter valued at about $52,000. Virtu Financial LLC grew its position in BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after acquiring an additional 6,868 shares during the last quarter. Finally, Menta Capital LLC bought a new position in BioScrip in the fourth quarter valued at about $124,000. Hedge funds and other institutional investors own 82.40% of the company’s stock.
About BioScrip (NASDAQ:BIOS)
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.